Capricor adcom setback leaves deramiocel fate with FDA
Capricor Therapeutics received an unfavourable advisory committee vote on Thursday when the FDA's Cellular, Tissue and Gene Therapies Advisory Committee concluded that available evidence did not support the effectiveness of deramiocel for cardiomyopathy in patients with Duchenne muscular dystrophy. The panel voted 9 against, 3 for, with no abstentions. The vote is non-binding, and the FDA retains full authority over the approval decision ahead of the company's PDUFA target action date of 22 August 2026.
Capricor was quick to note that the committee's voting question was framed around a narrower indication than the company had originally proposed, and did not encompass an assessment of the therapy's overall benefit-risk profile. In a separate discussion focused on upper limb function, committee members offered what Capricor described as directionally supportive feedback on evidence from the Phase 3 HOPE-3 trial, including results on its primary endpoint, the PUL 2.0 measure of upper limb performance. The public hearing that accompanied the meeting drew testimony from patients, families and clinicians, underscoring the scale of unmet need in the Duchenne community.
"We remain confident in the strength of the HOPE-3 data," said Linda Marbán, chief executive of Capricor. "In a moving open public hearing, patients, families, and clinicians shared their experience with the therapy, underscoring the unmet need within the Duchenne community."
The clinical and regulatory picture
Deramiocel consists of allogeneic cardiosphere-derived cells, which are understood to act primarily through secretion of exosomes. Those extracellular vesicles are thought to shift macrophage behaviour away from a pro-inflammatory state and toward tissue repair, with downstream effects on cardiac and skeletal muscle preservation. The therapy carries Orphan Drug Designation from both the FDA and the European Medicines Agency, as well as Regenerative Medicine Advanced Therapy designation and Rare Pediatric Disease Designation in the United States. The last of those designations would, upon approval, qualify Capricor for a Priority Review Voucher, which carry significant transferable value in the current market.
There is currently no approved treatment for cardiomyopathy in DMD patients, a population of roughly 15,000 in the United States. Progressive cardiac deterioration is the leading cause of death in the condition, which gives regulators and the patient community considerable motivation to find a workable regulatory path even after an adverse adcom vote.
Market context and what comes next
Adverse advisory committee votes do not preclude approval. The FDA has overruled its own advisory panels in a number of high-profile rare-disease cases in recent years, particularly where patient advocacy has been strong and unmet need is acute. The agency is also under sustained pressure from the rare-disease community and from Congress to interpret benefit-risk frameworks flexibly for conditions with no alternative.
For Capricor, the immediate priority is its pre-PDUFA engagement with the FDA. The company will need to address the committee's concerns around the narrowly framed effectiveness question while leaning on the skeletal muscle data and patient-reported evidence that drew more favourable commentary during the meeting. Investors will be focused on any label negotiation that emerges from those discussions, particularly on indication breadth, as a wider label substantially changes the commercial case for the therapy. The StealthX exosome delivery platform, which Capricor is also advancing, was not addressed in Thursday's announcement.